Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Saturday.
Other analysts have also recently issued research reports about the stock. Bank of America cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $2.90 to $2.50 in a report on Thursday, June 20th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday, October 2nd. Finally, Needham & Company LLC decreased their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.17.
View Our Latest Stock Report on ESPR
Esperion Therapeutics Stock Performance
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. On average, analysts predict that Esperion Therapeutics will post -0.04 earnings per share for the current year.
Hedge Funds Weigh In On Esperion Therapeutics
Several large investors have recently modified their holdings of ESPR. BOKF NA purchased a new stake in Esperion Therapeutics during the 2nd quarter valued at about $26,000. Xponance Inc. purchased a new stake in shares of Esperion Therapeutics during the second quarter valued at approximately $28,000. CVI Holdings LLC bought a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $37,000. Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics in the 2nd quarter worth approximately $44,000. Finally, National Bank of Canada FI lifted its position in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,225 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Read More
- Five stocks we like better than Esperion Therapeutics
- How to Calculate Return on Investment (ROI)
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.